Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.

Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ

Hypertension (Dallas, Tex. : 1979)30 Jun 2014Cited by 117 (Europe PMC)

PMID24980665DOI10.1161/hypertensionaha.114.03062PepBankPUB-24980665

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 0.75 mg was noninferior to placebo for 24-hour systolic pressure changes.
In plain wordsIn type 2 diabetes, dulaglutide 0.75 mg met noninferiority criteria versus placebo for systolic pressure changes.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicable24-hour systolic pressure noninferiority
Study
n: not reported in source
Comparator
placebo
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.75 mg weekly · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Both doses of dulaglutide were noninferior to placebo for changes in 24-hour SBP and diastolic blood pressure, and dulaglutide 1.5 mg significantly reduced SBP (least squares mean difference [95% confidence interval]), -2.8 mm Hg [-4.6, -1.0]; P≤0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was change from baseline to week 16 in mean 24-hour SBP, a tree gatekeeping strategy compared the effects of dulaglutide to placebo.
Summary · context
Patients (n=755; 56±10 years; 81% white; 48% women), with type 2 diabetes mellitus, taking ≥1 oral antihyperglycemic medication, with a clinic BP between 90/60 and 140/90 mm Hg were randomized to dulaglutide (1.5 or 0.75 mg) or placebo subcutaneously for 26 weeks.
Report a problemFND-2498066501
02HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 1.5 mg reduced 24-hour systolic pressure versus placebo.
In plain wordsIn type 2 diabetes, dulaglutide 1.5 mg reduced daily systolic pressure versus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
Decrease24-hour systolic pressure
Study
n: not reported in source
Comparator
placebo
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.5 mg weekly · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Systolic pressure difference
−2.8 mm Hg
versus placebo
Source sentences
Summary
Both doses of dulaglutide were noninferior to placebo for changes in 24-hour SBP and diastolic blood pressure, and dulaglutide 1.5 mg significantly reduced SBP (least squares mean difference [95% confidence interval]), -2.8 mm Hg [-4.6, -1.0]; P≤0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was change from baseline to week 16 in mean 24-hour SBP, a tree gatekeeping strategy compared the effects of dulaglutide to placebo.
Summary · context
Patients (n=755; 56±10 years; 81% white; 48% women), with type 2 diabetes mellitus, taking ≥1 oral antihyperglycemic medication, with a clinic BP between 90/60 and 140/90 mm Hg were randomized to dulaglutide (1.5 or 0.75 mg) or placebo subcutaneously for 26 weeks.
Report a problemFND-2498066502
03HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 0.75 mg was noninferior to placebo for 24-hour diastolic pressure changes.
In plain wordsIn type 2 diabetes, dulaglutide 0.75 mg met noninferiority criteria versus placebo for diastolic pressure changes.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicable24-hour diastolic pressure noninferiority
Study
n: not reported in source
Comparator
placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.75 mg weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Both doses of dulaglutide were noninferior to placebo for changes in 24-hour SBP and diastolic blood pressure, and dulaglutide 1.5 mg significantly reduced SBP (least squares mean difference [95% confidence interval]), -2.8 mm Hg [-4.6, -1.0]; P≤0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (n=755; 56±10 years; 81% white; 48% women), with type 2 diabetes mellitus, taking ≥1 oral antihyperglycemic medication, with a clinic BP between 90/60 and 140/90 mm Hg were randomized to dulaglutide (1.5 or 0.75 mg) or placebo subcutaneously for 26 weeks.
Report a problemFND-2498066503
04HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 1.5 mg was noninferior to placebo for 24-hour diastolic pressure changes.
In plain wordsIn type 2 diabetes, dulaglutide 1.5 mg met noninferiority criteria versus placebo for diastolic pressure changes.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicable24-hour diastolic pressure noninferiority
Study
n: not reported in source
Comparator
placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.5 mg weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Both doses of dulaglutide were noninferior to placebo for changes in 24-hour SBP and diastolic blood pressure, and dulaglutide 1.5 mg significantly reduced SBP (least squares mean difference [95% confidence interval]), -2.8 mm Hg [-4.6, -1.0]; P≤0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (n=755; 56±10 years; 81% white; 48% women), with type 2 diabetes mellitus, taking ≥1 oral antihyperglycemic medication, with a clinic BP between 90/60 and 140/90 mm Hg were randomized to dulaglutide (1.5 or 0.75 mg) or placebo subcutaneously for 26 weeks.
Report a problemFND-2498066504
05HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 0.75 mg was noninferior to placebo for 24-hour heart rate, with a least squares mean difference of 1.6 bpm.
In plain wordsIn type 2 diabetes, dulaglutide 0.75 mg met the noninferiority limit versus placebo for daily heart rate.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicable24-hour heart rate noninferiority
Study
n: not reported in source
Comparator
placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.75 mg weekly · subcutaneousAs given in this study (human).
Measurements
Heart-rate difference
1.6 bpm
versus placebo
Source sentences
Summary
Dulaglutide 0.75 mg was noninferior to placebo (1.6 bpm; [0.3, 2.9]; P≤0.02) for 24-hour heart rate (least squares mean difference [95% confidence interval]), but dulaglutide 1.5 mg was not (2.8 bpm [1.5, 4.2]).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (n=755; 56±10 years; 81% white; 48% women), with type 2 diabetes mellitus, taking ≥1 oral antihyperglycemic medication, with a clinic BP between 90/60 and 140/90 mm Hg were randomized to dulaglutide (1.5 or 0.75 mg) or placebo subcutaneously for 26 weeks.
Report a problemFND-2498066505
06HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, dulaglutide 1.5 mg increased 24-hour heart rate versus placebo and failed noninferiority.
In plain wordsIn type 2 diabetes, dulaglutide 1.5 mg increased daily heart rate versus placebo and failed noninferiority.
Peptide
Dulaglutide (Trulicity)
Outcome
Increase24-hour heart rate
Study
n: not reported in source
Comparator
placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.5 mg weekly · subcutaneousAs given in this study (human).
Measurements
Heart-rate difference
2.8 bpm
versus placebo
Source sentences
Summary
Dulaglutide 0.75 mg was noninferior to placebo (1.6 bpm; [0.3, 2.9]; P≤0.02) for 24-hour heart rate (least squares mean difference [95% confidence interval]), but dulaglutide 1.5 mg was not (2.8 bpm [1.5, 4.2]).
Summary
Dulaglutide 1.5 mg was associated with a reduction in 24-hour SBP and an increase in 24-hour heart rate.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (n=755; 56±10 years; 81% white; 48% women), with type 2 diabetes mellitus, taking ≥1 oral antihyperglycemic medication, with a clinic BP between 90/60 and 140/90 mm Hg were randomized to dulaglutide (1.5 or 0.75 mg) or placebo subcutaneously for 26 weeks.
Report a problemFND-2498066506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.

Summary

Results from this study6

Version history

Subjects

Publication types

MeSH terms

Keywords